Abiopharma

🔍 Moat Ross (Executive)

Company: Kiniksa Pharmaceuticals International, plc (KNSA)

Report Date: 2025-09-01

Detailed Transactions and Holdings:

• Acquired 1,741 shares of Class A Ordinary Share (Direct)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 11,156.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,611 shares of Class A Ordinary Share (Direct)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 12,767.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 2,477 shares of Class A Ordinary Share (Direct)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 15,244.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,819 shares of Class A Ordinary Share at $33.49 per share (Direct)
  Date: 2025-09-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 12,425.00 | transaction_form_type: 4
• Acquired 994 shares of Class A Ordinary Share (Direct)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 13,419.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 481 shares of Class A Ordinary Share at $34.28 per share (Direct)
  Date: 2025-09-02 | Code: F | equity_swap_involved: 0 | shares_owned_after: 12,938.00 | transaction_form_type: 4
• Acquired 9,828 shares of Restricted Share Unit (Derivative)
  Date: 2025-09-01 | Code: A | equity_swap_involved: 0 | shares_owned_after: 9,828.00 | transaction_form_type: 4 | Footnotes: F1, F2, F2
• Acquired 39,364 shares of Share Option at $33.49 per share (Derivative)
  Date: 2025-09-01 | Code: A | Expires: 2035-08-31 | equity_swap_involved: 0 | shares_owned_after: 39,364.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 1,741 shares of Restricted Share Unit (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 5,221.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4
• Sold 1,611 shares of Restricted Share Unit (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 3,222.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5
• Sold 2,477 shares of Restricted Share Unit (Derivative)
  Date: 2025-09-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,477.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6
• Sold 994 shares of Restricted Share Unit (Derivative)
  Date: 2025-09-02 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F7, F7

Footnotes:

• F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
• F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025.
• F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025.
• F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
• F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
• F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
• F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the vesting commencement date September 2, 2021.